Molecular docking and in vitro antileishmanial evaluation of chromene-2-thione analogues

ACS Medicinal Chemistry Letters

Volumn 3, Issue 3, 2012, Pages 243-247

  Verma, Rajiv Kumar ^a   Prajapati, Vijay Kumar ^b   Verma, Girijesh Kumar ^a   Chakraborty, Deblina ^c   Sundar, Shyam ^b   Rai, Madhukar ^b   Dubey, Vikash Kumar ^c   Singh, Maya Shankar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

chromene 2 thione; Lipinsky rule; molecular docking; trypanothione reductase; visceral leishmaniasis

Indexed keywords

3 THIEN 2OYL BENZO F 2H CHROMENE 2 THIONE; 6 BROMO 3 4 METHOXYBENZOYL 2H CHROMENE 2 THIONE; ANTILEISHMANIAL AGENT; CHROMENE DERIVATIVE; TRYPANOTHIONE REDUCTASE; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; AXENIC CULTURE; IN VITRO STUDY; LEISHMANIA DONOVANI; MOLECULAR DOCKING; NONHUMAN; OXIDATION REDUCTION REACTION; PARASITE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMASTIGOTE;

LEISHMANIA DONOVANI;

EID: 84858202164     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200280r     Document Type: Article

References (24)

1. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control ? Nat. Rev. Microbiol. 2007, 5, 873-882 (Pubitemid 47578388)
2. Murray, H. W.; Berman, J. D.; Davies, C. R.; Saravia, N. G. Advances in leishmaniasis Lancet 2005, 366, 1561-1577 (Pubitemid 41540115)
3. Grogl, M.; Thomason, T. N.; Franke, E. D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease Am. J. Trop. Med. Hyg. 1992, 47, 117-126
4. Kumar, D.; Kulshrestha, A.; Singh, R.; Salotra, P. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: Correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity Antimicrob. Agents Chemother. 2009, 53, 835-838
5. Tanoli, Z. M.; Rai, M. E.; Gandapur, A. S. Clinical presentation and management of visceral leishmaniasis J. Ayub. Med. Coll. Abbottabad 2005, 17, 51-53
6. Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug resistance in leishmaniasis Clin. Microbiol. Rev. 2006, 19, 111-126 (Pubitemid 43157649)
7. Sundar, S.; Jha, T. K.; Thakur, C. P.; Engel, J.; Sindermann, H.; Fischer, C.; Junge, K.; Bryceson, A.; Berman, J. Oral miltefosine for Indian visceral leishmaniasis N. Engl. J. Med. 2002, 347, 1739-1746 (Pubitemid 35375612)
8. Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.; Nicolaides, D. N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities Curr. Pharm. Des. 2004, 10, 3813-3833 (Pubitemid 39409872)
9. Hwu, J. R.; Singha, R.; Hong, S. C.; Chang, Y. H.; Das, A. R.; Vliegen, I.; De Clercq, E.; Neyts, J. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents Antiviral Res. 2008, 77, 157-162
10. Sardari, S.; Mori, Y.; Horita, K.; Micetich, R. G.; Nishibe, S.; Daneshtalab, M. Synthesis and antifungal activity of coumarins and angular furanocoumarins Bioorg. Med. Chem. 1999, 7, 1933-1940 (Pubitemid 29457691)
11. Spino, C.; Dodier, M.; Sotheeswaran, S. Anti-HIV coumarins from Calophyllum seed oil Bioorg. Med. Chem. Lett. 1998, 8, 3475-3478 (Pubitemid 29012561)
12. Arango, V.; Robledo, S.; SeÌ'on-MeÌ'niel, B.; FigadeÌ€re, B.; Cardona, W.; SaÌ'ez, J.; OtaÌ'lvaro, F. Coumarins from Galipea panamensis and their activity against Leishmania panamensis J. Nat. Prod. 2010, 73, 1012-1014
13. Ferreira, M. E.; de Arias, A. R.; Yaluff, G.; de Bilbao, N. V.; Nakayama, H.; Torres, S.; Schinini, A.; Guy, I.; Heinzen, H.; Fournet, A. Antileishmanial activity of furoquinolines and coumarins from Helietta apiculata Phytomedicine 2010, 17, 375-378
14. Iranshahi, M.; Arfa, P.; Ramezani, M.; Jaafari, M. R.; Sadeghian, H.; Bassarello, C.; Piacente, S.; Pizza, C. Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes Phytochemistry 2007, 68, 554-561 (Pubitemid 46186435)
15. Pierson, J. T.; Dumetre, A.; Hutter, S.; Delmas, F.; Laget, M.; Finet, J. P.; Azas, N.; Combes, S. Synthesis and antiprotozoal activity of 4-arylcoumarins Eur. J. Med. Chem. 2010, 45, 864-869
16. Singh, O. M.; Devi, N. S.; Thokchom, D. S.; Sharma, G. J. Novel 3-alkanoyl/aroyl/heteroaroyl-2 H -chromene-2-thiones: Synthesis and evaluation of their antioxidant activities Eur. J. Med. Chem. 2010, 45, 2250-2257
17. 3 under solvent-free conditions Tetrahedron 2011, 67, 584-589
18. Fairlamb, A. H.; Blackburn, P.; Ulrich, P.; Chait, B. T.; Cerami, A. Trypanothione: A novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids Science 1985, 227, 1485-1487 (Pubitemid 15146992)
19. Cinningham, M. L.; Fairlamb, A. H. Trypanothione Reductase from Leishmania Donovani: Purification, characterization and inhibition by trivalent Antimonials Eur. J. Biochem. 1995, 230, 460-468
20. Shukla, A. K.; Patra, S.; Dubey, V. K. Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: An alternative approach for chemotherapy of Leishmaniasis Mol. Cell. Biochem. 2011, 352, 261-270
21. Venkatesan, S. K.; Shukla, A. K.; Dubey, V. K. Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of Leishmania infantum J. Comput. Chem. 2010, 31, 2463-2475
22. Baiocco, P.; Colotti, G.; Franceschini, S.; Ilari, A. Molecular basis of antimony treatment in leishmaniasis J. Med. Chem. 2009, 52, 2603-2612
23. Chakravarty, J.; Sundar, S. Drug resistance in leishmaniasis J. Global Infect. Dis. 2010, 2, 167-176
24. Monzote, L.; Stamberg, W; Patel, A; Rosenau, T.; Maes, L; Cos, P; Gille, L. Synthetic chromanol derivatives and their interaction with complex III in Mitochondria from bovine, yeast, and leishmania Chem. Res. Toxicol. 2011, 24, 1678-1685